Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISK-ADAPT: Risk-Adapted Treatment Approaches in Metastatic Hormone-Sensitive Prostate Cancer
NCT07645326Phase 2Not yet recruiting
- Sponsor
- Georgetown University
- Start
- Dec 2026
- Primary completion
- Aug 2032
- Countries
- 1
01
Overview
Phase 2, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Georgetown University. Primary endpoint: Radiological Progression-Free Survival at 36 months. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07645326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645326.